29
Participants
Start Date
May 31, 2003
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2012
Alemtuzumab
Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
National Institutes of Health, National Cancer Institute, Bethesda
National Cancer Institute (NCI)
NIH